In episode 481, James and Mike invite Paul Fritsch to go through all the evidence for the benzoyl peroxide/adapalene and benzoyl peroxide/clindamycin combinations that we use for acne. Call us crazy, but we focus on the important outcome of whether or not the patient thinks the treatment worked. We provide all the info and very simple numbers that will help you with shared-decision making for your patients who are trying to figure out which product to use.

Show notes

Tools for Practice

Clearing up the evidence for topical acne combination products

In episode 480, James and Mike talk about two recent meta-analyses that have done a solid job of looking at the impact of lowering blood pressure and using SGLT-2s and GLP-1s to reduce risk. Both publications lend credence to the concept of focusing much more on risk reduction goals than blood pressure or glucose thresholds.

Show notes

1) Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

Lancet. 2021 May 1;397(10285):1625-1636.  

2) Decisions about antihypertensive treatment should focus on reducing cardiovascular risk

Lancet. 2021 May 1;397(10285):1598-1599

3) Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

BMJ. 2021 Jan 13;372:m4573.  doi: 10.1136/bmj.m4573.